3D Medicines (1244.HK) has a profit margin of -42.43%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
The latest profit margin for 1244.HK is -42.43% as of June 2026. That compares with -111.85% in the prior-year period — up 62.1% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside 3D Medicines's historical trend and sector peers before judging valuation or financial health.
Over the past year, 1244.HK's profit margin moved from -111.85% to -42.43% — a 62.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 3D Medicines's valuation or profitability profile.
Against Healthcare companies, 1244.HK currently prints -42.43% for profit margin, while the sector average sits near 17.63%. That is roughly 340.7% below the sector mean. Large gaps often invite a closer look at 3D Medicines's growth, margins, and balance sheet.
Profit Margin shows how effectively 3D Medicines converts resources into returns. At -42.43%, 1244.HK may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -111.85% in the prior-year period — up 62.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 1244.HK's profit margin (-42.43%), review year-over-year change from -111.85%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.